Clinical Trial Update: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing glufosfamide to 5-fluorouracil in patients with second-line metastatic pancreatic adenocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Glufosfamide (glufosfamide)

Snippet

Sponsor: Eleison Pharmaceuticals LLC. | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 3 | Status: RECRUITING